

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/835,298	04/13/2001	Jeffrey R. Dahlen	071959-5301	4762
75	90 10/21/2002			
Michael A. Whittaker			EXAMINER	
FOLEY & LARDNER			GABEL, GAILENE	
23rd Floor				
402 West Broadway San Diego, CA 92101-3542		ART UNIT	PAPER NUMBER	
_ 1080, 011			1641	
			DATE MAILED: 10/21/2002	8

Please find below and/or attached an Office communication concerning this application or proceeding.

*	Application No.	Applicant(s)	
	09/835,298	DAHLEN ET AL.	
Office Action Summary	Examiner	Art Unit	_
	Gailene R. Gabel	1641	
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with	the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rep - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut - Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a repoly within the statutory minimum of thirty (will apply and will expire SIX (6) MONTH e, cause the application to become ABA	ly be timely filed 30) days will be considered timely. IS from the mailing date of this communication. NDONED (35 U.S.C. § 133).	
Status 1) Responsive to communication(s) filed on 08	August 2002		
1) Responsive to communication(s) filed on <u>08</u> 2a) This action is FINAL . 2b) This action is FINAL .	his action is non-final.		
3) Since this application is in condition for allow		ire prosecution as to the merits is	
closed in accordance with the practice under Disposition of Claims			
4)⊠ Claim(s) <u>1-9,11-19 and 22</u> is/are pending in t	he application.		
4a) Of the above claim(s) is/are withdra	wn from consideration.		
5) Claim(s) is/are allowed.	· .		
6)☐ Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8)⊠ Claim(s) <u>1-9,11-19 and 22</u> are subject to restr	iction and/or election require	ment.	
Application Papers			
9)☐ The specification is objected to by the Examine	er.		
10) The drawing(s) filed on is/are: a) acce	epted or b) objected to by the	Examiner.	
Applicant may not request that any objection to the			
11)☐ The proposed drawing correction filed on	_ is: a)∭ approved b)∭ dis	approved by the Examiner.	
If approved, corrected drawings are required in re			
12) The oath or declaration is objected to by the Ex	kaminer.		
Priority under 35 U.S.C. §§ 119 and 120			
13) Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C. §	119(a)-(d) or (f).	
a) ☐ All b) ☐ Some * c) ☐ None of:			
1. Certified copies of the priority document	ts have been received.		
2. Certified copies of the priority document	ts have been received in App	lication No	
3. Copies of the certified copies of the price application from the International But See the attached detailed Office action for a list	ureau (PCT Rule 17.2(a)).		
14) Acknowledgment is made of a claim for domest	ic priority under 35 U.S.C. §	119(e) (to a provisional application)).
a) The translation of the foreign language pro			
Attachment(s)	. ,	-	
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Inf	mmary (PTO-413) Paper No(s) ormal Patent Application (PTO-152)	

Application/Control Number: 09/835,298

Art Unit: 1641

DETAILED ACTION

Election/Restrictions

Amendment Entry

- 1. Applicant's election of Group I, claims 1-9, with traverse in Paper No. 7 is acknowledged and has been entered. Applicant's amendment is also acknowledged and has been entered. Claims 10 and 20-21 have been cancelled. Claim 22 has been added. Claims 1 and 11 have been amended. Currently, claims 1-9, 11-19, and 22 are pending. Accordingly, a restriction requirement has been set forth in light of the newly submitted claim in addition to the claims currently pending of record which are deemed to encompass three groups of inventions.
- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-8, 11-18, and 22, drawn to a method of detecting a polypeptide from pre-pro B-type natriuretic peptide to determine non-ST elevation acute coronary syndrome, classified in class 435, subclass 6, for example.
 - II. Claim 9, drawn to detecting a level of B-type natriuretic peptide as a prognostic marker in addition to a panel of prognostic markers to predict increased risk in non-ST-elevation acute coronary syndrome, classified in class 435, subclass 973, for example.
 - III. Claim 19, drawn to detecting a level of a marker related to B-type natriuretic peptide as a prognostic marker in addition to a panel of

Application/Control Number: 09/835,298

Art Unit: 1641

prognostic markers to predict increased risk in non-ST-elevation acute coronary syndrome, classified in class 435, subclass 973, for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, II, and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation, different functions, and different effects in that Invention 1 determines pre-pro B-type natriuretic peptide to determine non-ST elevation acute coronary syndrome, Invention II uses B-type natriuretic peptide as a prognostic marker in addition to a panel of prognostic markers to predict increased risk in non-ST-elevation acute coronary syndrome, and Invention III uses a marker related to B-type natriuretic peptide as a prognostic marker in addition to a panel of prognostic marker to predict increased risk in non-ST-elevation acute coronary syndrome.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper. Furthermore, because the search required for Group I is not required for Group II, and the search required for Group II is not required for Group III, restriction for examination purposes as indicated is proper. Literature search for each method is distinct since the structural requirements of each invention are different. While searches would be expected to overlap, there is no reason to expect the searches to be coextensive.

Application/Control Number: 09/835,298

Art Unit: 1641

3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gailene R Gabel whose telephone number is (703) 305-0807. The examiner can normally be reached on Monday-Thursday 6:00 AM to 3:30 PM and alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (703) 305-3399. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Page 5

Gailene R. Gabel October 17, 2002

> CHRISTOPHER L. CHIN PRIMARY EXAMINER GROUP_18007/64/

Christoph L. Chri